CTOs on the Move

Contego Medical

www.contegomedical.com

 
Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Contego Medical raised $22M on 01/13/2020

Similar Companies

Tri-therapy Inc

Tri-therapy Inc is a Searcy, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedLite ID

MedLite ID is an easy-to-use, disposable medical device that enables clinicans to accurately and efficiently identify a single medication infusion line against similar infusion lines in any light setting. The ninth leading cause of medical-error deaths in the United States involves infusion line confusion, and nearly 65 percent of those cases are related to the medication infusion line. MedLite ID eliminates infusion confusion by providing indicators with built-in wireless light technology at the medication bag, connector, and to patient. Each MedLite ID device is unique to its individual medication infusion line and cuts the process of infusion line identification to mere seconds. This saves clinicians precious time while also drastically mitigating risk and reducing stress while ensuring better care and patient outcomes.

Benson's Surgical

Benson's Surgical is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VeriTeQ Corp

VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.

Osiris Therapeutics

Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation. In Biosurgery, we harness the ability of cells and novel constructs to promote the body`s natural healing. The goals are to improve surgical outcomes and offer better treatment options for patients and physicians. We like a challenge, so the focus is in areas where we believe we can have a significant impact. Difficult indications and challenging cases are targeted. Osiris has been studying tissue engineering since the beginning, and its dedicated team conducted groundbreaking research in the field. The work in bone led to the development of the successful product Osteocel, now owned by NuVasive Inc. Now, application of these technologies is being expanded beyond bone, to soft tissues, such as cartilage and tendon, and also wound healing.